PROFILE FOR VTGN.
EARNINGS HISTORY
| -0.02 MISS | Nov, 07, 2024 Actual: -0.42 Estimated: -0.4 |
| +0.06 BEAT | Aug, 13, 2024 Actual: -0.35 Estimated: -0.41 |
| +0.09 BEAT | Jun, 11, 2024 Actual: -0.25 Estimated: -0.34 |
| +0.09 BEAT | Feb, 13, 2024 Actual: -0.22 Estimated: -0.31 |
| +0.02 BEAT | Nov, 09, 2023 Actual: -0.66 Estimated: -0.68 |
| -0.25 MISS | Jun, 22, 2023 Actual: -1.75 Estimated: -1.5 |
| +0.3 BEAT | Feb, 07, 2023 Actual: -1.5 Estimated: -1.8 |
| 0 MET | Nov, 10, 2022 Actual: -2.4 Estimated: -2.4 |
NEWS FEED
 | Vistagen Initiates Fasedienol Repeat Dose Study for the Acute Treatment of Social Anxiety Disorder 2025-01-10 08:30:00 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced enrollment of the first subject in a repeat dose study of fasedienol, its investigational neuroactive pherine nasal spray in Phase 3 development for the acute treatment of social anxiety disorder (SAD). The repeat dose study is a small exploratory U.S. Phase 2 multi-center, randomized, double-blind, place. |  | Vistagen to Present at the Stifel 2024 Healthcare Conference 2024-11-14 08:30:00 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $VTGN #mentalhealth–Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that company management will present and host one-on-one meetings during the Stifel 2024 Healthcare Conference taking place November 18 and 19, 2024 in New York City. Stifel 2024 Healthcare Conference Shawn Singh, Chief Executive Officer, will participate in a fireside chat on Monday, November 18 at 3:35. |  | Vistagen Therapeutics, Inc. (VTGN) Q2 2025 Earnings Call Transcript 2024-11-10 07:43:56 Vistagen Therapeutics, Inc. (NASDAQ:VTGN ) Q2 2025 Earnings Conference Call November 7, 2024 5:00 PM ET Company Participants Mark McPartland – SVP, IR Shawn Singh – CEO Cindy Anderson – CFO Josh Prince – COO Conference Call Participants Julian Pino – Stifel Andrew Tsai – Jefferies Myles Minter – William Blair Madison El-Saadi – B. Riley Securities Operator Good afternoon, ladies and gentlemen, and welcome to the Vistagen Therapeutics Fiscal Year 2025 Second Quarter Corporate Update Conference Call. |  | VistaGen Therapeutics, Inc. (VTGN) Reports Q2 Loss, Misses Revenue Estimates 2024-11-07 20:31:31 VistaGen Therapeutics, Inc. (VTGN) came out with a quarterly loss of $0.42 per share versus the Zacks Consensus Estimate of a loss of $0.40. This compares to loss of $0.66 per share a year ago. |  | Vistagen Reports Fiscal Year 2025 Second Quarter Financial Results and Corporate Update 2024-11-07 16:20:00 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $VTGN #mentalhealth–Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today reported financial results for its fiscal year 2025 second quarter ended September 30, 2024, and provided a corporate update. “We initiated our PALISADE-4 Phase 3 trial during our second quarter, achieving yet another significant milestone in our fasedienol U.S. registration-directed Phase 3 Program for the acute t. |  | Vistagen to Present at the 2024 Neuroscience Education Institute Congress 2024-11-05 08:30:00 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $VTGN #mentalhealth–Vistagen (Nasdaq: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced that it will present posters highlighting new prevalence data for social anxiety disorder (SAD), an indication for which fasedienol, its lead intranasal pherine product candidate, is in U.S. registration-directed Phase 3 development for the acute treatment of the disorder, and two additional non-systemic. |  | Vistagen to Report Fiscal Year 2025 Second Quarter Results and Host Corporate Update Conference Call on November 7, 2024 2024-11-01 08:30:00 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)—- $VTGN #mentalhealth–Vistagen (NASDAQ: VTGN), a late clinical-stage company dedicated to pioneering neuroscience based on nose-to-brain neurocircuitry, today announced it will host a conference call and webcast on Thursday, November 7, 2024, at 2:00 p.m. Pacific Time (5:00 p.m. Eastern Time) to report results for its fiscal year 2025 second quarter ended September 30, 2024, and provide a corporate update. Event: Vistagen Fiscal Year 2025 Second Quarter Corporate Update. |  | Vistagen Could Run Up Ahead Of Phase 3 Results In Social Anxiety Disorder 2024-10-15 07:25:52 Vistagen’s fasedienol nasal spray is in two phase 3 trials for social anxiety disorder, with results expected in 2025. Positive results from PALISADE-2 were seen previously, and VTGN may need only one of the two studies, PALISADE-3 and PALISADE-4, to succeed in supporting a filing for marketing approval. VTGN had $108.4M as of June 30, 2024, but increased R&D expenses may accelerate cash burn, and the Company could look to use its at-the-market facility or conduct an offering. |  | VistaGen Therapeutics (VTGN) Upgraded to Buy: Here’s What You Should Know 2024-10-11 13:01:12 VistaGen Therapeutics (VTGN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term. |  | Vistagen, The Goldie Hawn Foundation, and MindUP Students to Ring Nasdaq Closing Bell on World Mental Health Day 2024-10-09 08:30:00 SOUTH SAN FRANCISCO, Calif. & SANTA MONICA, Calif.–(BUSINESS WIRE)—- $VTGN #mentalhealth–Vistagen (Nasdaq: VTGN), a late clinical-stage neuroscience-focused biopharmaceutical company dedicated to the development of groundbreaking therapies for psychiatric disorders based on nose-to-brain neurocircuitry, and The Goldie Hawn Foundation’s MindUP, a neuroscience-based preventative mental health program for youth, along with children from New York City schools utilizing MindUP, will join together in New York City on Oc. |